Dyne Therapeutics Stock Surges 11% Week-to-Date Amid Analyst Note

Dyne Therapeutics stock surged 11% week-to-date after a positive mention in an analyst note by RBC Capital Markets. The biotech company focuses on developing therapies for muscle disorders, including myotonic dystrophy, which has an estimated addressable patient population of 95,000 individuals in the US and EU. The sector still has potential for further increases as investors rotate out of AI/tech titles and into healthcare/biotech stocks.